Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On - Report - MDSpire

Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On

Breakthrough treatments for gastrointestinal cancers are being tested in clinical trials right now.

  • By

  • May 20, 2026

  • 9 min

Share

Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On

Overview

This report highlights the importance of early consultation about clinical trials for patients with gastrointestinal cancers. Breakthrough treatments are being tested, and participation in clinical trials can provide access to novel therapies that may significantly impact patient outcomes.

Background

Clinical trials are essential for advancing treatment options in gastrointestinal cancers, which are often complex and require tailored approaches. Early involvement in clinical trials can provide patients with access to cutting-edge therapies and potentially improve their prognosis. Awareness among patients and healthcare providers about the availability of these trials is crucial for optimizing treatment decisions.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

  • Clinical trials offer patients access to novel therapies throughout their cancer journey.
  • USC Norris Comprehensive Cancer Center has over 50 therapeutic trials for gastrointestinal malignancies.
  • New immunotherapy agents and targeted therapies are expanding treatment options for esophagogastric cancers.
  • Early-phase studies at USC include trials assessing new drugs and combinations for advanced cancers.
  • Patients should be informed about clinical trial options before starting standard treatments.

Clinical Implications

Healthcare providers should prioritize discussions about clinical trial participation early in the treatment process for patients with gastrointestinal cancers. This approach can enhance patient access to innovative therapies and improve overall treatment outcomes.

Conclusion

Engaging patients in discussions about clinical trials from the outset is vital for maximizing treatment opportunities in gastrointestinal oncology. Early awareness and participation can lead to better patient outcomes.

Related Resources & Content

  1. The ASCO Post, 2015 -- Our Patients Are the True Heroes of Cancer Research
  2. The ASCO Post, 2014 -- Clinical Trials Actively Recruiting Patients With Colon or Rectal Cancer
  3. The ASCO Post, 2016 -- Educating People About Clinical Trials May Improve Their Likelihood of Participation
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2024
  5. FDA, 2024 -- FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
  6. The New Gastroenterologist — Proactively Addressing Gastrointestinal Cancers in Younger Populations
  7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
  8. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer | FDA
  9. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial | Nature Medicine

Original Source(s)

Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On

  • by

  • May 20, 2026

Related Content

Turning Medical Insights into Patient Impact

Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes

Rethinking Progress in Clinical Trials

Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development

  • May 20, 2026

  • 11 min
Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min